BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhanji RA, Carey EJ, Watt KD. Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease. Aliment Pharmacol Ther. 2017;46:16-25. [PMID: 28464346 DOI: 10.1111/apt.14078] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Macdonald S, Jepsen P, Alrubaiy L, Watson H, Vilstrup H, Jalan R. Quality of life measures predict mortality in patients with cirrhosis and severe ascites. Aliment Pharmacol Ther 2019;49:321-30. [PMID: 30585338 DOI: 10.1111/apt.15084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
2 de Wit K, Schaapman JJ, Nevens F, Verbeek J, Coenen S, Cuperus FJC, Kramer M, Tjwa ETTL, Mostafavi N, Dijkgraaf MGW, van Delden OM, Beuers UHW, Coenraad MJ, Takkenberg RB. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol 2020;7:e000531. [PMID: 33372103 DOI: 10.1136/bmjgast-2020-000531] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Woodland H, Hudson B, Forbes K, McCune A, Wright M; British Association for the Study of the Liver (BASL) End of Life Special Interest Group. Palliative care in liver disease: what does good look like? Frontline Gastroenterol 2020;11:218-27. [PMID: 32419913 DOI: 10.1136/flgastro-2019-101180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kimbell B, Murray SA, Byrne H, Baird A, Hayes PC, MacGilchrist A, Finucane A, Brookes Young P, O'Carroll RE, Weir CJ, Kendall M, Boyd K. Palliative care for people with advanced liver disease: A feasibility trial of a supportive care liver nurse specialist. Palliat Med 2018;32:919-29. [PMID: 29516776 DOI: 10.1177/0269216318760441] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
5 Gallach M, Vergara M, da Costa JP, Miquel M, Casas M, Sanchez-Delgado J, Dalmau B, Rudi N, Parra I, Monllor T, Sanchez-Lloansí M, Dosal A, Valero O, Calvet X. Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS One 2018;13:e0208112. [PMID: 30566421 DOI: 10.1371/journal.pone.0208112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kawaratani H, Moriya K, Namisaki T, Shimozato N, Kaji K, Takaya H, Fujinaga Y, Sawada Y, Sato S, Saikawa S, Kubo T, Akahane T, Fukui H, Yoshiji H. Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Exp Ther Med 2021;21:30. [PMID: 33262816 DOI: 10.3892/etm.2020.9462] [Reference Citation Analysis]
7 Mazzarelli C, Prentice WM, Heneghan MA, Belli LS, Agarwal K, Cannon MD. Palliative care in end-stage liver disease: Time to do better? Liver Transpl 2018;24:961-8. [PMID: 29729119 DOI: 10.1002/lt.25193] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
8 Riedel AN, Kimer N, Jensen ASH, Dahl EK, Israelsen M, Aamann L, Gluud LL. Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients. World J Gastroenterol 2018; 24(15): 1650-1657 [PMID: 29686472 DOI: 10.3748/wjg.v24.i15.1650] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Stepanova M, Nader F, Bureau C, Adebayo D, Elkrief L, Valla D, Peck-radosavljevic M, Mccune A, Vargas V, Simon-talero M, Cordoba J, Angeli P, Rossi S, Macdonald S, Capel J, Jalan R, Younossi ZM. Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. Qual Life Res 2018;27:1513-20. [DOI: 10.1007/s11136-018-1813-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
10 Tovoli F, De Lorenzo S, Samolsky Dekel BG, Piscaglia F, Benevento F, Brandi G, Bolondi L. Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. Liver Int 2018;38:278-84. [PMID: 28792650 DOI: 10.1111/liv.13546] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
11 Gazineo D, Godino L, Bui V, El Mouttaqi L, Franciosi E, Natalino A, Ceci G, Ambrosi E. Health-related quality of life in outpatients with chronic liver disease: a cross-sectional study. BMC Gastroenterol 2021;21:318. [PMID: 34364363 DOI: 10.1186/s12876-021-01890-7] [Reference Citation Analysis]
12 Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther 2020;51:64-77. [PMID: 31701570 DOI: 10.1111/apt.15571] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
13 Steiner JM, Kovacs AH. Adults with congenital heart disease – Facing morbidities and uncertain early mortality. Progress in Pediatric Cardiology 2018;48:75-81. [DOI: 10.1016/j.ppedcard.2018.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]